Jazz agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million contingent. The asset is ABS-1230, a first-in-class oral KCNT1 ion channel inhibitor for KCNT1-positive epilepsy, a developmental and epileptic encephalopathy affecting roughly 2,500 US patients with no approved therapy. Around 80% have disease onset in infancy. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study.

Sixty two percent committed at signing, for a drug that has been through one early proof-of-concept trial.

The number that justifies it is not the patient count. It is RDEP. ABS-1230 was accepted into FDA’s new Rare Disease Evidence Principles programme, alongside Fast Track, Orphan Drug and Rare Pediatric Disease designations, and RDEP exists to let ultra-rare therapies register on less evidence than a conventional programme requires. Jazz is not buying a Phase 1b asset at Phase 3 prices. It is buying a Phase 1b asset it believes is a registrational asset, and KYRON is the test of whether that belief holds. Note the structure too: Actio spins its remaining assets, including the Charcot-Marie-Tooth programme ABS-0871, into a new private company with Jazz taking a minority stake. Jazz bought one molecule and optioned the rest.

PTC is purchasing ST-920, a one-time intravenous AAV gene therapy for Fabry disease, from Sangamo Therapeutics. Sangamo filed for Chapter 11 protection on 23 June 2026. Sangamo separately confirmed successful bidders across a competitive asset auction totalling $163.55 million in cash consideration.

A filed BLA changed hands for $111 million. That is the price of a gene therapy asset when the seller has no choice.

Read it against the rest of the week. Jazz paid $820 million for a molecule that has completed one early trial; PTC paid $111 million for one that has completed its pivotal programme and reached a filing. The difference is not clinical risk, it is seller leverage. Chapter 11 converts a regulatory-stage asset into a distressed one regardless of its data, and an auction clears at what buyers will pay in a forced process rather than at anything resembling fair value. For anyone modelling gene therapy asset values, this datapoint matters more than any headline licensing deal this year.

Beyond Jazz and PTC, Sobi took exclusive worldwide rights to Innate Pharma’s lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma, at $75 million upfront against $580 million. Sentynl took an exclusive worldwide option on Mereo’s alvelestat in alpha-1 antitrypsin deficiency lung disease at $40 million against $475 million.

Four different rare indications, four different structures, one destination.

The structural spread inside those four deals is the interesting part. Jazz committed 62% at signing for an outright acquisition. Sobi paid 13% and took on the commercial burden while Innate runs the confirmatory Phase III TELLOMAK-3. Sentynl paid 8% for an option, keeping the right to walk before committing to a US launch, with Mereo retaining rest of world. Each buyer priced the same category of risk differently according to how much of the development it agreed to carry. Read the upfront ratio next to who runs the trial, never on its own.

HealthCare Royalty, a KKR company, purchased OPKO Health’s royalty rights to mazdutide, an approved dual GLP-1 and glucagon receptor agonist for obesity. Royalty Pharma purchased Zealand Pharma’s rights to a 1% royalty on worldwide net sales of rusfertide, a Phase III peptide for polycythemia vera, plus regulatory and commercial milestones.

Non-dilutive capital, priced off someone else’s launch.

Both sellers converted a passive future income stream into cash today without touching their share count. That is the right move when a company believes its own equity is undervalued and its royalty is not: sell the asset the market prices efficiently and keep the one it does not. The buyers are doing the mirror image. Royalty Pharma is buying a 1% slice of a Phase III asset it has no role in developing, and HealthCare Royalty is buying into an approved obesity drug where commercial risk is lowest and the revenue curve is steepest. Two royalty monetizations in one week is not a trend yet, but log it against a financing market where the IPO window has only recently reopened.

Teledyne is acquiring Varex Imaging for $1.1 billion in cash, taking X-ray tubes, photon-counting detectors, high-voltage components and imaging software that supply the medical imaging OEMs. Elsewhere, Revolution Medicines granted BeOne exclusive rights to develop and commercialise four RAS(ON) inhibitors including daraxonrasib, Curium acquired Abscint’s PET radiodiagnostic pipeline, Alfasigma agreed to acquire Nordic Group, and IASO Bio acquired MediSix Therapeutics. None disclosed terms.

The week’s biggest all-cash deal bought components, not molecules.

Varex is the same trade as KKR and Integer a fortnight ago: a supplier whose revenue attaches to other companies’ product cycles, where regulatory qualification and validated tooling act as switching costs. Buyers keep paying full cash for these because the flows are predictable and public markets discount them. The undisclosed tail is where the genuinely strategic news sits, and the Revolution Medicines pact with BeOne is the one to chase. Four RAS(ON) inhibitors including a Phase III pancreatic cancer asset moving to a partner without a published number means the terms are either unusual or unfinished.